Chapter V. Beta-Cell Replacement

Rev Diabet Stud, 2012, 9(4):385-406 DOI 10.1900/RDS.2012.9.385

Islet Transplantation in Type 1 Diabetes: Ongoing Challenges, Refined Procedures, and Long-Term Outcome

A.M. James Shapiro

Clinical Islet Transplant Program, University of Alberta, 2000 College Plaza, 8215 112th Street, Edmonton AB Canada T6G 2C8

Manuscript submitted December 16, 2012; accepted January 21, 2013.

Keywords: diabetes, islet, transplantation, immunosuppression, allograft

Abstract

Remarkable progress has been made in islet transplantation over a span of 40 years. Once just an experimental curiosity in mice, this therapy has moved forward, and can now provide robust therapy for highly selected patients with type 1 diabetes (T1D), refractory to stabilization by other means. This progress could not have occurred without extensive dynamic international collaboration. Currently, 1,085 patients have undergone islet transplantation at 40 international sites since the Edmonton Protocol was reported in 2000 (752 allografts, 333 autografts), according to the Collaborative Islet Transplant Registry. The long-term results of islet transplantation in selected centers now match registry data of pancreas-alone transplantation, with 6 sites reporting five-year insulin independence rates ≥50%. Islet transplantation has been criticized for the use of multiple donor pancreas organs, but progress has also occurred in single-donor success, with 10 sites reporting increased single-donor engraftment. The next wave of innovative clinical trial interventions will address instant blood-mediated inflammatory reaction (IBMIR), apoptosis, and inflammation, and will translate into further marked improvements in single-donor success. Effective control of auto- and alloimmunity is the key to long-term islet function, and high-resolution cellular and antibody-based assays will add considerable precision to this process. Advances in immunosuppression, with new antibody-based targeting of costimulatory blockade and other T-B cellular signaling, will have further profound impact on the safety record of immunotherapy. Clinical trials will move forward shortly to test out new human stem cell derived islets, and in parallel trials will move forward, testing pig islets for compatibility in patients. Induction of immunological tolerance to self-islet antigens and to allografts is a difficult challenge, but potentially within our grasp.

Fulltext: HTML , PDF (327KB)


This article has been cited by other articles:

The potential use of cell-based therapies in the treatment of oral diseases

Kagami H

Oral Dis 2015. In press

Bioengineered stem cells as an alternative for islet cell transplantation

Moore SJ, Gala-Lopez BL, Pepper AR, Pawlick RL, Shapiro AM

World J Transplant 2015. In press

Cell sheet approach for tissue engineering and regenerative medicine

Matsuura K, Utoh R, Nagase K, Okano T

J Control Release 2014. 190:228-239

Beta-cell differentiation of human pancreatic duct-derived cells after in vitro expansion

Corritore E, Dugnani E, Pasquale V, Misawa R, Witkowski P, Piemonti L, Sokal EM, Lysy PA

Cell Reprogram 2014. 16(6):456-466

From Beta cell replacement to beta cell regeneration: implications for antidiabetic therapy

Liu C, Wu H

J Diabetes Sci Technol 2014. 8(6):1221-1226

An Extremely Weak Electric Current System Induces Anti-apoptotic Effects and Anti-necrotic Effects in Living Cells

Kojima D, Nishinakamura H, Itoh T, Kodama S

Curr Tissue Engin 2014. 3(2):102-111

Maturation of stem cell-derived beta-cells guided by the expression of urocortin 3

van der Meulen T, Huising MO

Rev Diabet Stud 2014. 11(1):115-132

Islet and stem cell encapsulation for clinical transplantation

Krishnan R, Alexander M, Robles L, Foster CE 3rd, Lakey JR

Rev Diabet Stud 2014. 11(1):84-101

In vitro differentiation and expansion of human pluripotent stem cell-derived pancreatic progenitors

Chmielowiec J, Borowiak M

Rev Diabet Stud 2014. 11(1):19-34

Theranostic MRI: the future for Type 1 diabetes management?

Wang P, Moore A

Imaging Med 2014. 6(1):25-39

Synergism of a natural plant product, oleanolic acid with calcineurin inhibitor in prolonging islet allograft survival

Angaswamy N, Tiriveedhi V, Banan B, Benshoff N, Chapman W, Mohanakumar T

Transpl Immunol 2013. 29(1-4):64-70

Islet neogenesis: a possible pathway for Beta-cell replenishment

Bonner-Weir S, Guo L, Li WC, Ouziel-Yahalom L, Weir GC, Sharma A

Rev Diabet Stud 2012. 9(4):407-416

Interleukin-1 antagonists and other cytokine blockade strategies for Type 1 diabetes

Mandrup-Poulsen T

Rev Diabet Stud 2012. 9(4):338-347